Edit |   |
---|---|
Product Name | CD40 Antibody Kit, anti-human, APC, REAlease® |
Description | CD40 Antibody Kit, anti-human, APC, REAlease®. Clone REAL131 is an antibody fragment derived from the full CD40 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL131 recognizes the human CD40 antigen, a transmembrane receptor of the tumor necrosis factor gene superfamily. CD40 is a co-stimulatory protein constitutively expressed by antigen presenting cells, including dendritic cells, B cells, and macrophages and on endothelial, smooth muscle cells, and fibroblasts. The binding of CD40 to CD154 (CD40L) on T helper cells activates antigen presenting cells and enhances the expression of cytokines, chemokines, matrix metalloproteinases, growth factors, and adhesion molecules. CD40 has been shown to interact with members of the TRAF family. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
Size | 100 tests |
Concentration | 1:50 |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Other Names | Bp50, CD40L receptor, CDW40 |
Gene, Accession, CAS # | n/a |
Catalog # | 130-122-681 |
Price | $440 |
Order / More Info | CD40 Antibody Kit, anti-human, APC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Stamenkovic, I. et al. (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 8 (5): 1403-1410. | Sato, T. et al. (1995) A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett. 358 (2): 113-118. | Chatzigeorgiou, A. et al. (2009) CD40/CD40L signaling and its implication in health and disease. Biofactors 35 (6): 474-483. |